search
Back to results

Use of GnRHa During Chemotherapy for Fertility Protection (ProFertil)

Primary Purpose

Breast Cancer Female, Acute Leukemia, Lymphoma

Status
Not yet recruiting
Phase
Phase 3
Locations
Sweden
Study Type
Interventional
Intervention
Triptorelin Embonate
Sodium Chloride solution 0.9%
Sponsored by
Kenny Rodriguez-Wallberg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer Female focused on measuring Fertility protection of young women receiving chemotherapy

Eligibility Criteria

14 Years - 42 Years (Child, Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent
  • Breast cancer or acute leukemias, lymphomas (Hodgkin and non-Hodgkin) or sarcomas (osteo, soft tissue and Ewing) confirmed by histology and assigned for diseace-specific chemotheraphy
  • Confirmed menarche
  • ECOG performance status 0-1
  • Adequate bone marrow, renal, hepatic and cardiac functions and absence of other uncontrolled medical or psychiatric disorders

Exclusion Criteria:

  • Demonstrated premature ovarian failure at time of randomization according to clinical or biochemical data
  • Previous or planned bilateral oophorectomy
  • Pregnancy or breastfeeding at time of start of chemotherapy
  • Other malignancy diagnosed within the last five years
  • Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders including previous or current diagnosis of anorexia
  • Known osteoporosis
  • Known low platelet count with increased bleeding risk or refractory thrombocytopenia in subjects with acute leukemias
  • Known or suspected allergy against triptorelin
  • Direct radiation of the gonads previous or planned (TBI allowed)
  • Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation

Sites / Locations

  • Center for Pediatric Cancer, Queen Silvia Hospital for Children and Youth
  • Center for Pediatric Oncology, Akademiska Hospital
  • Department of Oncology, Sahlgrenska University Hospital
  • Department of Hematology, Skåne University Hospital
  • Department of Oncology, Skåne University Hospital
  • Department of Pediatric Oncology, Skåne University Hospital
  • Karolinska Univeristy Hospital, Breast Centre
  • Department of Hematology and coagulation, Sahlgrenska University Hospital
  • Department of Hematology, Capio ST. Göran Hospital
  • Department of Internal Medicine, Södersjukhuset
  • Department of Oncology, Capio ST. Göran Hospital
  • Department of Oncology, Södersjukhuset
  • Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet
  • Karolinska University Hospital, Hematology
  • Karolinska University Hospital, High Specialised Pediatric Medicine
  • Department of Oncology, Norrlands University Hospital
  • Department of Oncology, Örebro University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Arm A: Triptorelin

Arm B: Placebo

Arm Description

Triptorelin given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment. The dose is ether 11.25 mg triptorelin given for subjects having at least 3 months gonadotoxic treatment, OR 3.75 mg for subjects during one-month of gonadotoxic treatment

Placebo, 0.9% sodium chloride, given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment. The dose will be provided both as one injection compensating for 3 months' effect and one injection compensating for 1 month' effect to maintain the study blind.

Outcomes

Primary Outcome Measures

Anti-Müllerian Hormone (AMH) levels in women with breast cancer
To estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the AMH relative to AMH levels at EoT in women with breast cancer.

Secondary Outcome Measures

Anti-Müllerian Hormone (AMH) levels in women with acute leukemias, lymphomas and sarcomas.
To estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the AMH relative to AMH levels at EoT in women with acute leukemias, lymphomas and sarcomas.
Changes in ovarian reserve with or without Gonadotropin-Releasing Hormone agonist (GnRHa) by determination of the antral follicle counts (AFC)
Changes in AFC in women with breast cancer and with acute leukemia, lymphoma and sarcoma respectively
Changes in ovarian reserve with or without GnRHa by longitudinal observation of AMH levels
The difference in recovery of AMH levels between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively
The proportion of females with or without GnRHa that develop ovarian insufficiency by determination of follicle stimulating hormone (FSH), inhibin and estradiol
Comparison of FSH, inhibin and estradiol between the GnRHa group and the placebo group
Impact of body mass index (BMI) (Kg/m2) on changes in ovarian reserve with or without GnRHa
longitudinal observation of AMH levels, FSH, inhibin and estradiol
Impact of use of contraceptives (yes/no) in changes of ovarian reserve with or without GnRHa
longitudinal observation of AMH levels, FSH, inhibin and estradiol
Impact of endocrine adjuvant therapy (yes/no) in changes of ovarian reserve with or without GnRHa
longitudinal observation of AMH levels, FSH, inhibin and estradiol
The effect of GnRHa with or without GnRHa on ovarian blood supply
Comparison of blood flow to the ovarian artery (right and left Doppler flow) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively
The proportion of females with or without GnRHa that develop amenorrhea (no menstruations)
Comparison of the proportion that develop amenorrhea (no menstruations) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively
Pregnacy wish after cancer treatment in women with or without GnRHa who attempt pregnancy during follow-up
Comparison of of pregnancy wish (Study specific questionaire) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Fertility and childbirth after cancer treatment in women with or without GnRHa who attempt pregnancy during follow-up
Comparison of pregnancy attempts (Study specific questionaire) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Fertility and childbirth after cancer treatment in women with or without GnRHa who attempt pregnancy during follow-up
Comparison of pregnancy outcome between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Health-related quality of life (EORTC QLQ C30)
Comparison of validated outcome on health-related QoL (EORTC QLQ C30) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Health-related quality of life (FSFI)
Comparison of validated outcome of sexuality and reproductive health (Female Sexual Function Index (FSFI)) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Health-related quality of life (HAD)
Comparison of validated outcome on health-related QoL (Hospital Anxiety and Depression Scale (HAD)) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
The development of co-morbidities during follow-up and bone mineral density
Comparison of bone mineral density between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Disease-specific oncologic outcomes: disease-free survival
Investigation of disease-free survival between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Disease-specific oncologic outcomes: Recurrence rate
Investigation of recurrence rate between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Disease-specific oncologic outcomes: overall survival
Investigation of overall survival between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.

Full Information

First Posted
March 29, 2022
Last Updated
March 6, 2023
Sponsor
Kenny Rodriguez-Wallberg
search

1. Study Identification

Unique Protocol Identification Number
NCT05328258
Brief Title
Use of GnRHa During Chemotherapy for Fertility Protection
Acronym
ProFertil
Official Title
A Phase 3 Randomised Double-Blinded Placebo-Controlled Study of Use of GnRHa During Chemotherapy for Fertility Protection of Young Women and Teenagers With Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 31, 2023 (Anticipated)
Primary Completion Date
January 1, 2028 (Anticipated)
Study Completion Date
January 31, 2032 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Kenny Rodriguez-Wallberg

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Many cytotoxic drugs may harm the fertility of young women treated for cancer. The aim of the study is to investigate if the Gonadotropin-Releasing Hormone agonist (GnRHa) during cancer treatment can preserve the fertility of young female cancer subjects. Approximately 300 women with newly diagnosed breast cancer and up to 200 women with newly diagnosed lymphoma, acute leukemias or sarcomas will be recruited before start of cancer treatment. The patients will be randomised in between treatment with triptorelin (experimental) or placebo (control) intramuscularly a 1:1 ratio during chemotherapy. The injections may be given once monthly or once three months depending on type of chemotherapy given. Randomisation and study drug is blinded, neither investigator, research nurse nor patient will know if it is active drug or placebo. The only person who knows is the nurse preparing the injection. Patients will be followed up to 5 years after end of treatment with physical examinations, vital signs, biochemical markers, bone mineral density exams, ultrasound for antral follicle counts and ovarian doppler flow, concomitant medications, adverse events and quality of life questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma, Soft Tissue Sarcoma, Ewing Sarcoma
Keywords
Fertility protection of young women receiving chemotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Prospective, randomised, double-blinded, placebo-controlled, phase 3 study
Masking
ParticipantCare ProviderInvestigator
Masking Description
Subjects are randomised to triptorelin (active arm) or placebo (control) given in parallel to the chemotherapy treatment for the cancer diagnosis. All personnel involved in the study, and subjects, except personnel preparing triptorelin/placebo at the local site and an unblinded monitor, will be blinded during the study. Unblinded research nurse at each site will prepare blinded triptorelin/placebo to subjects and a web-based randomisation system will be used to allocate of blinded triptorelin/placebo to subjects at randomisation and drug dispense during the treatment period.
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A: Triptorelin
Arm Type
Experimental
Arm Description
Triptorelin given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment. The dose is ether 11.25 mg triptorelin given for subjects having at least 3 months gonadotoxic treatment, OR 3.75 mg for subjects during one-month of gonadotoxic treatment
Arm Title
Arm B: Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo, 0.9% sodium chloride, given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment. The dose will be provided both as one injection compensating for 3 months' effect and one injection compensating for 1 month' effect to maintain the study blind.
Intervention Type
Drug
Intervention Name(s)
Triptorelin Embonate
Other Intervention Name(s)
Pamorelin
Intervention Description
11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug. 3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug.
Intervention Type
Drug
Intervention Name(s)
Sodium Chloride solution 0.9%
Other Intervention Name(s)
Placebo
Intervention Description
One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
Primary Outcome Measure Information:
Title
Anti-Müllerian Hormone (AMH) levels in women with breast cancer
Description
To estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the AMH relative to AMH levels at EoT in women with breast cancer.
Time Frame
12 months after end of gonadotoxic chemotherapy and study drug treatment
Secondary Outcome Measure Information:
Title
Anti-Müllerian Hormone (AMH) levels in women with acute leukemias, lymphomas and sarcomas.
Description
To estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the AMH relative to AMH levels at EoT in women with acute leukemias, lymphomas and sarcomas.
Time Frame
12 months after end of gonadotoxic chemotherapy and study drug treatment
Title
Changes in ovarian reserve with or without Gonadotropin-Releasing Hormone agonist (GnRHa) by determination of the antral follicle counts (AFC)
Description
Changes in AFC in women with breast cancer and with acute leukemia, lymphoma and sarcoma respectively
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months) and at 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT
Title
Changes in ovarian reserve with or without GnRHa by longitudinal observation of AMH levels
Description
The difference in recovery of AMH levels between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively
Time Frame
At 6 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
The proportion of females with or without GnRHa that develop ovarian insufficiency by determination of follicle stimulating hormone (FSH), inhibin and estradiol
Description
Comparison of FSH, inhibin and estradiol between the GnRHa group and the placebo group
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Impact of body mass index (BMI) (Kg/m2) on changes in ovarian reserve with or without GnRHa
Description
longitudinal observation of AMH levels, FSH, inhibin and estradiol
Time Frame
At Baseline, during treatment, at end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Impact of use of contraceptives (yes/no) in changes of ovarian reserve with or without GnRHa
Description
longitudinal observation of AMH levels, FSH, inhibin and estradiol
Time Frame
At Baseline, during treatment visits (every 1-3 months of gonadotoxic treatment), at end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Impact of endocrine adjuvant therapy (yes/no) in changes of ovarian reserve with or without GnRHa
Description
longitudinal observation of AMH levels, FSH, inhibin and estradiol
Time Frame
At Baseline, during treatment visits (every 1-3 months of gonadotoxic treatment), at end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
The effect of GnRHa with or without GnRHa on ovarian blood supply
Description
Comparison of blood flow to the ovarian artery (right and left Doppler flow) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
The proportion of females with or without GnRHa that develop amenorrhea (no menstruations)
Description
Comparison of the proportion that develop amenorrhea (no menstruations) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Pregnacy wish after cancer treatment in women with or without GnRHa who attempt pregnancy during follow-up
Description
Comparison of of pregnancy wish (Study specific questionaire) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Fertility and childbirth after cancer treatment in women with or without GnRHa who attempt pregnancy during follow-up
Description
Comparison of pregnancy attempts (Study specific questionaire) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At end of chemotherapy (corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Fertility and childbirth after cancer treatment in women with or without GnRHa who attempt pregnancy during follow-up
Description
Comparison of pregnancy outcome between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Health-related quality of life (EORTC QLQ C30)
Description
Comparison of validated outcome on health-related QoL (EORTC QLQ C30) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Health-related quality of life (FSFI)
Description
Comparison of validated outcome of sexuality and reproductive health (Female Sexual Function Index (FSFI)) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Health-related quality of life (HAD)
Description
Comparison of validated outcome on health-related QoL (Hospital Anxiety and Depression Scale (HAD)) between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months), and 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
The development of co-morbidities during follow-up and bone mineral density
Description
Comparison of bone mineral density between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At baseline, at end of gonadotoxic chemotherapy (EoT; corresponding to Baseline+2-11 months) and 12 months and 5 years after EoT
Title
Disease-specific oncologic outcomes: disease-free survival
Description
Investigation of disease-free survival between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Disease-specific oncologic outcomes: Recurrence rate
Description
Investigation of recurrence rate between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At 12 months, 2 years, 3 years, 4 years and 5 years after EoT.
Title
Disease-specific oncologic outcomes: overall survival
Description
Investigation of overall survival between the GnRHa group and the placebo group in women with breast cancer and in women with acute leukemia, lymphoma and sarcoma respectively.
Time Frame
At 12 months, 2 years, 3 years, 4 years and 5 years after EoT.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent Breast cancer or acute leukemias, lymphomas (Hodgkin and non-Hodgkin) or sarcomas (osteo, soft tissue and Ewing) confirmed by histology and assigned for diseace-specific chemotheraphy Confirmed menarche ECOG performance status 0-1 Adequate bone marrow, renal, hepatic and cardiac functions and absence of other uncontrolled medical or psychiatric disorders Exclusion Criteria: Demonstrated premature ovarian failure at time of randomization according to clinical or biochemical data Previous or planned bilateral oophorectomy Pregnancy or breastfeeding at time of start of chemotherapy Other malignancy diagnosed within the last five years Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders including previous or current diagnosis of anorexia Known osteoporosis Known low platelet count with increased bleeding risk or refractory thrombocytopenia in subjects with acute leukemias Known or suspected allergy against triptorelin Direct radiation of the gonads previous or planned (TBI allowed) Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kenny Rodriguez Wallberg, MD, PhD
Phone
+46 858580000
Email
kenny.rodriguez-wallberg@ki.se
First Name & Middle Initial & Last Name or Official Title & Degree
Hanna Nilsson, PhD
Email
hanna.nilsson@ki.se
Facility Information:
Facility Name
Center for Pediatric Cancer, Queen Silvia Hospital for Children and Youth
City
Göteborg
Country
Sweden
Facility Name
Center for Pediatric Oncology, Akademiska Hospital
City
Göteborg
Country
Sweden
Facility Name
Department of Oncology, Sahlgrenska University Hospital
City
Göteborg
Country
Sweden
Facility Name
Department of Hematology, Skåne University Hospital
City
Lund
Country
Sweden
Facility Name
Department of Oncology, Skåne University Hospital
City
Lund
Country
Sweden
Facility Name
Department of Pediatric Oncology, Skåne University Hospital
City
Lund
Country
Sweden
Facility Name
Karolinska Univeristy Hospital, Breast Centre
City
Stockholm
ZIP/Postal Code
17176
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Theo Foukakis, MD, PhD
Email
theo.foukakis@ki.se
Facility Name
Department of Hematology and coagulation, Sahlgrenska University Hospital
City
Stockholm
Country
Sweden
Facility Name
Department of Hematology, Capio ST. Göran Hospital
City
Stockholm
Country
Sweden
Facility Name
Department of Internal Medicine, Södersjukhuset
City
Stockholm
Country
Sweden
Facility Name
Department of Oncology, Capio ST. Göran Hospital
City
Stockholm
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erika Isaksson Friman
Facility Name
Department of Oncology, Södersjukhuset
City
Stockholm
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Linder-Stragliotto
Facility Name
Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet
City
Stockholm
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per Ljungman
Facility Name
Karolinska University Hospital, Hematology
City
Stockholm
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Harrysson, MD, PhD
Email
sara.harrysson@regionstockholm.se
Facility Name
Karolinska University Hospital, High Specialised Pediatric Medicine
City
Stockholm
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan Malmros, MD, PhD
Email
johan.malmros@ki.se
Facility Name
Department of Oncology, Norrlands University Hospital
City
Umeå
Country
Sweden
Facility Name
Department of Oncology, Örebro University Hospital
City
Örebro
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Use of GnRHa During Chemotherapy for Fertility Protection

We'll reach out to this number within 24 hrs